ExploreWatchlistsPricing
  1. JP-listed companies
  2. Kidswell Bio Corporation
  3. Financials
  4. Net income margin (%)

Kidswell Bio Corporation (4584)

Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income margin (%) YoY (%)
Mar 31, 2025-0.4-99.29%
Mar 31, 2024-58.5+147.00%
Mar 31, 2023-23.7-30.57%
Mar 31, 2022-34.1-66.06%
Mar 31, 2021-100.5-85.20%
Mar 31, 2020-678.9+710.01%
Mar 31, 2019-83.8-1.81%
Mar 31, 2018-85.4-24.07%
Mar 31, 2017-112.4+65.67%
Mar 31, 2016-67.9-72.45%
Mar 31, 2015-246.3+42.92%
Mar 31, 2014-172.3-72.33%
Mar 31, 2013-622.9+301.91%
Mar 31, 2012-155

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat